Andria Wilk - Argen X Global Quality

ARGX Stock  EUR 553.60  21.40  4.02%   

Insider

Andria Wilk is Global Quality of Argen X
Age 49
Phone31 10 703 8441
Webhttps://www.argenx.com

Argen X Management Efficiency

The company has return on total asset (ROA) of (0.1649) % which means that it has lost $0.1649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3064) %, meaning that it generated substantial loss on money invested by shareholders. Argen X's management efficiency ratios could be used to measure how well Argen X manages its routine affairs as well as how well it operates its assets and liabilities.
Argen X has accumulated 9.7 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Argen X has a current ratio of 10.85, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Argen X until it has trouble settling it off, either with new capital or with free cash flow. So, Argen X's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Argen X sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Argen to invest in growth at high rates of return. When we think about Argen X's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

William SilbeyUCB SA
64
Sofie GijselGalapagos NV
N/A
Marieke VermeerschGalapagos NV
N/A
Chantal TassetGalapagos NV
N/A
Geert ReyndersMelexis NV
N/A
Reginald GenechtenBiocartis Group NV
57
Kirsten LundJurgensenUCB SA
64
Herman VerrelstBiocartis Group NV
49
Susy SpruytBiocartis Group NV
55
Karen GriensvenMelexis NV
53
JeanMarc RoelandtBiocartis Group NV
58
Geert MaertensBiocartis Group NV
N/A
Heidi StieglitzMelexis NV
63
Erwin SablonBiocartis Group NV
58
Benoit DevogelaereBiocartis Group NV
42
John MontanaGalapagos NV
N/A
Piet HouwenBiocartis Group NV
55
Pr LowFriedrichUCB SA
63
MBA MBAGalapagos NV
53
Michele MBAGalapagos NV
N/A
Renate DegraveBiocartis Group NV
N/A
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. ARGENX SE operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. It employs 650 people. Argen X (ARGX) is traded on Euronext Brussels in Belgium and employs 650 people.

Management Performance

Argen X Leadership Team

Elected by the shareholders, the Argen X's board of directors comprises two types of representatives: Argen X inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Argen. The board's role is to monitor Argen X's management team and ensure that shareholders' interests are well served. Argen X's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Argen X's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karl Gubitz, Chief Officer
Beth DelGiacco, VP Relations
Malini Moorthy, G Counsel
EMBA MBA, CEO Director
Filip Borgions, VP Operations
Pr Ir, CoFounder Officer
Keith Woods, Chief Officer
Arjen MSc, VP Strategy
David MD, Advisor
Andria Wilk, Global Quality

Argen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Argen X a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Argen X

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Argen X position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Argen X will appreciate offsetting losses from the drop in the long position's value.

Moving against Argen Stock

  0.91CFEB Compagnie d Entreprises Earnings Call TomorrowPairCorr
  0.82BNB Banque nationalePairCorr
The ability to find closely correlated positions to Argen X could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Argen X when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Argen X - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Argen X to buy it.
The correlation of Argen X is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Argen X moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Argen X moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Argen X can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Argen Stock Analysis

When running Argen X's price analysis, check to measure Argen X's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argen X is operating at the current time. Most of Argen X's value examination focuses on studying past and present price action to predict the probability of Argen X's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argen X's price. Additionally, you may evaluate how the addition of Argen X to your portfolios can decrease your overall portfolio volatility.